Compare NVVE & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVVE | GCTK |
|---|---|---|
| Founded | 1996 | 2001 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Oil Refining/Marketing | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 1.6M |
| IPO Year | N/A | 2011 |
| Metric | NVVE | GCTK |
|---|---|---|
| Price | $0.83 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 258.2K | 37.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17910.53 |
| EPS | N/A | ★ 30.09 |
| Revenue | N/A | ★ $589,462.00 |
| Revenue This Year | $892.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.04 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.09 |
| 52 Week High | $5.69 | $15.90 |
| Indicator | NVVE | GCTK |
|---|---|---|
| Relative Strength Index (RSI) | 36.51 | 24.82 |
| Support Level | $0.83 | $0.09 |
| Resistance Level | $1.13 | $4.24 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 8.00 | 24.07 |
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.